Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients - PubMed (original) (raw)
Clinical Trial
. 2003 Aug;52(8):1943-50.
doi: 10.2337/diabetes.52.8.1943.
Affiliations
- PMID: 12882909
- DOI: 10.2337/diabetes.52.8.1943
Clinical Trial
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients
Yoshinori Miyazaki et al. Diabetes. 2003 Aug.
Abstract
Thiazolidinediones (TZDs) improve glycemic control and insulin sensitivity in patients with type 2 diabetes. To determine whether the TZD-induced improvement in glycemic control is associated with enhanced insulin receptor signaling in skeletal muscle, 20 type 2 diabetic patients received a 75-g oral glucose tolerance test (OGTT) and euglycemic insulin (80 mU x m(-2) x min(-1)) clamp with [3-(3)H]glucose/indirect calorimetry/vastus lateralis muscle biopsies before and after 16 weeks of rosiglitazone treatment. Six age-matched nondiabetic subjects served as control subjects. RSG improved fasting plasma glucose (185 +/- 8 to 139 +/- 5 mg/dl), mean plasma glucose during the OGTT (290 +/- 9 to 225 +/- 6 mg/dl), HbA(1c) (8.5 +/- 0.3 to 7.1 +/- 0.3%), insulin-mediated total-body glucose disposal (TGD) (6.9 +/- 0.7 to 9.2 +/- 0.8 mg x kg(-1) fat-free mass x min(-1)) (all P < 0.001), and decreased fasting plasma free fatty acid (FFA) (789 +/- 59 to 656 +/- 50 micro Eq/l) and mean FFA during the OGTT (644 +/- 41 to 471 +/- 35 micro Eq/l) (both P < 0.01). Before RSG treatment, insulin infusion did not significantly increase insulin receptor tyrosine phosphorylation (0.95 +/- 0.10 to 1.08 +/- 0.13 density units; NS) but had a small stimulatory effect on insulin receptor substrate (IRS)-1 tyrosine phosphorylation (1.05 +/- 0.10 to 1.21 +/- 0.12 density units; P < 0.01) and the association of p85 with IRS-1 (0.94 +/- 0.06 to 1.08 +/- 0.06 activity units; P < 0.01). RSG therapy had no effect on basal or insulin-stimulated insulin receptor tyrosine phosphorylation but increased insulin stimulation of IRS-1 tyrosine phosphorylation (1.13 +/- 0.11 to 1.56 +/- 0.17 density units; P < 0.01 vs. prerosiglitazone) and p85 association with IRS-1 (1.00 +/- 0.06 to 1.27 +/- 0.07 activity units; P < 0.05 vs. prerosiglitazone). In control and type 2 diabetic subjects, TGD/nonoxidative glucose disposal correlated positively with the insulin-stimulated increments in IRS-1 tyrosine phosphorylation (r = 0.52/r = 0.57, P < 0.01) and inversely with the plasma FFA concentration during the insulin clamp (r = -0.55/r = -0.53, P < 0.01). However, no significant association between plasma FFA concentrations during the insulin clamp and the increment in either IRS-1 tyrosine phosphorylation or the association of p85 with IRS-1 was observed. In conclusion, in type 2 diabetic patients, rosiglitazone treatment enhances downstream insulin receptor signaling in muscle and decreases plasma FFA concentration while improving glycemic control.
Similar articles
- Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Beeson M, Sajan MP, Dizon M, Grebenev D, Gomez-Daspet J, Miura A, Kanoh Y, Powe J, Bandyopadhyay G, Standaert ML, Farese RV. Beeson M, et al. Diabetes. 2003 Aug;52(8):1926-34. doi: 10.2337/diabetes.52.8.1926. Diabetes. 2003. PMID: 12882907 Clinical Trial. - Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Diabetes Care. 2001 Apr;24(4):710-9. doi: 10.2337/diacare.24.4.710. Diabetes Care. 2001. PMID: 11315836 Clinical Trial. - Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA. Miyazaki Y, et al. Diabetologia. 2001 Dec;44(12):2210-9. doi: 10.1007/s001250100031. Diabetologia. 2001. PMID: 11793023 Clinical Trial. - Free fatty acids, insulin resistance, and type 2 diabetes mellitus.
Boden G. Boden G. Proc Assoc Am Physicians. 1999 May-Jun;111(3):241-8. doi: 10.1046/j.1525-1381.1999.99220.x. Proc Assoc Am Physicians. 1999. PMID: 10354364 Review. - [Rosiglitazone (BRL-49653)].
Kameda N, Okuya S, Oka Y. Kameda N, et al. Nihon Rinsho. 2000 Feb;58(2):401-4. Nihon Rinsho. 2000. PMID: 10707565 Review. Japanese.
Cited by
- Iodine Promotes Glucose Uptake through Akt Phosphorylation and Glut-4 in Adipocytes, but Higher Doses Induce Cytotoxic Effects in Pancreatic Beta Cells.
Arely RJ, Cristian AE, Omar AX, Antonio PJ, Isela SR, Yeimy Mar LR, Xcaret Alexa HD, Omar AH. Arely RJ, et al. Biology (Basel). 2024 Jan 1;13(1):26. doi: 10.3390/biology13010026. Biology (Basel). 2024. PMID: 38248457 Free PMC article. - The Regulatory Roles of PPARs in Skeletal Muscle Fuel Metabolism and Inflammation: Impact of PPAR Agonism on Muscle in Chronic Disease, Contraction and Sepsis.
Crossland H, Constantin-Teodosiu D, Greenhaff PL. Crossland H, et al. Int J Mol Sci. 2021 Sep 10;22(18):9775. doi: 10.3390/ijms22189775. Int J Mol Sci. 2021. PMID: 34575939 Free PMC article. Review. - From Pre-Diabetes to Diabetes: Diagnosis, Treatments and Translational Research.
Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. Khan RMM, et al. Medicina (Kaunas). 2019 Aug 29;55(9):546. doi: 10.3390/medicina55090546. Medicina (Kaunas). 2019. PMID: 31470636 Free PMC article. Review. - Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.
Di Pino A, DeFronzo RA. Di Pino A, et al. Endocr Rev. 2019 Dec 1;40(6):1447-1467. doi: 10.1210/er.2018-00141. Endocr Rev. 2019. PMID: 31050706 Free PMC article. Review. - An aPPARent Functional Consequence in Skeletal Muscle Physiology via Peroxisome Proliferator-Activated Receptors.
Phua WWT, Wong MXY, Liao Z, Tan NS. Phua WWT, et al. Int J Mol Sci. 2018 May 10;19(5):1425. doi: 10.3390/ijms19051425. Int J Mol Sci. 2018. PMID: 29747466 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous